HIV drug Aptivus gains new indication approval for kids
Boehringer Ingelheim's Aptivus can now be used to treat HIV-infected pediatric patients.
Pediatric patients between two and 18 years of age who are infected with HIV have a new treatment available to them. It’s Boehringer Ingelheim Pharmaceuticals’
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
